What Does it Mean to be a Manufacturer of Choice?
Ritedose explains how quality, reliability, and Blow-Fill-Seal (BFS) expertise define what it means to be a true manufacturer of choice in pharmaceutical manufacturing.
READ MORE
IN THE NEWS
Solutions
Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing
Pharmaceutical manufacturing at scale requires flexibility, cGMP compliance and advanced technology to ensure safe, reliable medications for patients.
READ MORE
Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing
Blow-Fill-Seal manufacturing is transforming sterile pharmaceutical production, and Ritedose is setting the standard through innovation, quality systems and scalable CDMO expertise.
READ MORE
How Ritedose Addresses Drug Shortages
Ritedose helps address drug shortages by using advanced sterile manufacturing and strategic partnerships to keep essential treatments available.
READ MORE
Ritedose Honored With SCbio’s 2026 Life Sciences Pinnacle Award for Organizational Contribution
South Carolina’s largest sterile CDMO recognized for visionary leadership, innovation, and community impact at SCbio’s annual Life + Science Conference.
READ MORE
South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub
Ritedose is helping shape a new era of innovation in South Carolina, where life sciences companies are scaling faster than ever before.
READ MORE
Ritedose 2025 Year-In-Review
Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.
READ MORE
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…
READ MORE
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
READ MORE
How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery
Discover how Ritedose leads the industry in delivering safe, scalable, and contamination-free drug products through advanced BFS innovation.
READ MORE
Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml
COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new…
READ MORE
FEATURED NEWS
RECEIVE THE LATEST NEWS
Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.